FDA Drug Safety Podcast: FDA warns about increased risk of cancer relapse with long-term use of azithromycin (Zithromax, Zmax) antibiotic after donor stem cell transplant
FDA Drug Safety podcast on azithromycin (Zithromax, Zmax) antibiotic (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: podcasts

Updates On The FORTE Trial: 3 Arm Study, Higher Amount Of Persistent MRD At One Year In Patients Who Received A Transplant
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Updates On The FORTE Trial: 3 Arm Study, Higher Amount Of Persistent MRD At One Year In Patients Who Received A Tr... Author: Annual-Meeting Added: 06/13/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 14, 2019 Category: Cancer & Oncology Source Type: podcasts

Smoldering Myeloma ECOG Trial: Patients With Intermediate & High Risk MM Had An Improved Time To Progression Compared To Those Being Observed
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Smoldering Myeloma ECOG Trial: Patients With Intermediate & High Risk MM Had An Improved Time To Progression Compa... Author: Annual-Meeting Added: 06/13/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 14, 2019 Category: Cancer & Oncology Source Type: podcasts

IMWG Classification Of Smoldering Myeloma: Incorporates Earlier Features Of Disease, When You Have At Least 1 Cytogenetic Abnormality It Increases Progression
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses IMWG Classification Of Smoldering Myeloma: Incorporates Earlier Features Of Disease, When You Have At Least 1 Cyto... Author: Annual-Meeting Added: 06/13/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 14, 2019 Category: Cancer & Oncology Source Type: podcasts

Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results From CheckMate 040: ORR of 14 & mOS of 16 Months, First Report of Efficacy & Safety of The NIVO + IPI combo in SOR-Treated patients With aHCC
Thomas Yau MD, MBBS Of University of Hong Kong Discusses Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results From CheckMate 040: ORR of 14& mOS of 16 Months, First Report of Efficacy & ... Author: Annual-Meeting Added: 06/13/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 14, 2019 Category: Cancer & Oncology Source Type: podcasts

JAMA Otolaryngology –Head & Neck Surgery : Prognostic Case Volume Thresholds in Patients With Head and Neck Squamous Cell Carcinoma
Interview with Benjamin L. Judson, MD, author of Prognostic Case Volume Thresholds in Patients With Head and Neck Squamous Cell Carcinoma (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - June 13, 2019 Category: General Medicine Source Type: podcasts

Bringing Primary Physician Back Into The Care Of Patients With Cancer: Not All Primary Care Physicians Feel Comfortable Or Would Like To Engage With Their Patients While They Are Getting Cancer Care
Larissa Nekhlyudov MD MPH Of Brigham & Womens Hospital/Dana-Farber Cancer Institute, Harvard Medical School Discusses Bringing Primary Physician Back Into The Care Of Patients With Cancer: Not All Pr... Author: Annual-Meeting Added: 06/12/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2019 Category: Cancer & Oncology Source Type: podcasts

Need To Optimize Communication & Care Coordination: Sexual Health Is Important & Doctors Need To Ask Questions About It, Electronic Health Records Have Potential To Improve Communication
Larissa Nekhlyudov MD MPH Of Brigham & Womens Hospital/Dana-Farber Cancer Institute, Harvard Medical School Discusses Need To Optimize Communication & Care Coordination: Sexual Health Is Important & ... Author: Annual-Meeting Added: 06/12/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2019 Category: Cancer & Oncology Source Type: podcasts

Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials
Aref Al-Kali MD Of The Mayo Clinic Discusses Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials. Author: Annual-Meeting Added: 06/12/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2019 Category: Cancer & Oncology Source Type: podcasts

How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine & Decitabine, When To Dose Reduce A Drug & When To Give Less Days Of The Drug
Aref Al-Kali MD Of The Mayo Clinic Discusses How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine & Decitabine, When To Dose Reduce A Drug & When To Give Less Days Of The Drug. Author: Annual-Meeting Added: 06/12/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2019 Category: Cancer & Oncology Source Type: podcasts

If They Are Imaging Negative, How Are They Responding: No Imaging Modality Is Perfect, 80% Use Plain Imaging Which Is Not As Sensitive As What Were Doing Now
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses If They Are Imaging Negative, How Are They Responding: No Imaging Modality Is Perfect, 80% Use Plain Imaging ... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced ... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Targeting PSMA: Patients That Have At Least One Bright Image Tend To Have A Better Chance At Responding
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses Targeting PSMA: Patients That Have At Least One Bright Image Tend To Have A Better Chance At Responding.... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Treatment Sequencing For Castrate Resistant M0 Disease: Looking At 3 Drugs Enzalutamide, Apalutamide, & Darolutamide, The Options Are The Challenge
Mark Fleming MD Of US Oncology Research Discusses Treatment Sequencing For Castrate Resistant M0 Disease: Looking At 3 Drugs Enzalutamide, Apalutamide, & Darolutamide, The Options Are The Challenge. Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

TITAN Trial: Many Options Including Chemo, Abiraterone, Enzalutamide, & Apalutamide All Showing A Benefit
Mark Fleming MD Of US Oncology Research Discusses TITAN Trial: Many Options Including Chemo, Abiraterone, Enzalutamide, & Apalutamide All Showing A Benefit. Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of Interest In This Study, Encorafenib Was Superior To Vemurafenib
Keith T. Flaherty, M.D. Of Array BioPharma Discusses Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of Interest In This Study, Encorafenib Was Superior To Vemurafenib.BACK... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Updates On Patient Care From ASCO: New Ways To Educate Patients Like Micro-learning Videos, Analysis About Cost-Effective Breast Cancer Screening
Neelima Denduluri MD @ndenduluri1 Of US Oncology Research Discusses Updates On Patient Care From ASCO: New Ways To Educate Patients Like Micro-learning Videos, Analysis About Cost-Effective Breast Can... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
Lowell Anthony MD Of Markey Cancer Center Discusses When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Lowell Anthony MD Of Markey Cancer Center Discusses Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy. Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Lowell Anthony MD Of Markey Cancer Center Discusses Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability Produced By This Mutation
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depend On What Is Happening In Their Tumor
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depen... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median Onset Of Response Was 3 Months, Median Followup Of Slightly More Than 7 Months
Joshua Allen PhD @jallenphd Of Oncoceutics, Inc. Discusses Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median Onset Of Response Was 3 Months, Median Followup Of Slightly M... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Using Steroids To Mitigate Cytokine-Release Syndrome: Did Not See Any Grade 3, 4, Or 5 Cytokine-Release Syndrome When Adding Steroids
Max S. Topp MD Of University Hospital of Wuerzburg Discusses Using Steroids To Mitigate Cytokine-Release Syndrome: Did Not See Any Grade 3, 4, Or 5 Cytokine-Release Syndrome When Adding Steroids. Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Mitigate Cytokine-Release Syndrome With Steroids In Practice: If Only 10Of Patients End Up In The ICU Compared To 30That Is Significant In Practice
Max S. Topp MD Of University Hospital of Wuerzburg Discusses Mitigate Cytokine-Release Syndrome With Steroids In Practice: If Only 10Of Patients End Up In The ICU Compared To 30That Is Significant In ... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

The Process Of Tumor Genesis & Tumor Cells Response To Therapy: Its Predicted That If You Could Target Stress Relief Programs You Might Get Much More Efficient Therapy
Joan Brugge PhD Of Harvard Medical School Discusses The Process Of Tumor Genesis & Tumor Cells Response To Therapy: Its Predicted That If You Could Target Stress Relief Programs You Might Get Much Mor... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Updates In The Thoracic Oncology Field: We Now Have Specific Inhibitors That Are Producing Durable Responses & Interesting Activity In Terms Of PFS & OS
Giorgio Scagliotti MD @giorgioscaglio3 Of University of Torino Discusses Updates In The Thoracic Oncology Field: We Now Have Specific Inhibitors That Are Producing Durable Responses & Interesting Acti... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Updates On Sarcomatoid & Rhabdoid Renal Cell Carcinoma: Immune Checkpoint Inhibitors Are Doing Really Well In Sarcomatoid RCC
Ziad Bakouny MD @ZiadBakouny Of Dana-Farber Cancer Institute Discusses Updates On Sarcomatoid & Rhabdoid Renal Cell Carcinoma: Immune Checkpoint Inhibitors Are Doing Really Well In Sarcomatoid RCC. Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Using A.I. & amp; Predictive Analytics In Healthcare: Will Augment Physicians Decisions As Opposed To Replace Them & amp; Provide Appropriate Choice Architecture
Debra Patt MD @dapattmd Of US Oncology Research Discusses Using A.I. & Predictive Analytics In Healthcare: Will Augment Physicians Decisions As Opposed To Replace Them & Provide Appropriate Ch... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Delivering Innovated Care In The Clinic: Innovations Made In The Clinic Have Been Transformative In Terms Of Improving The Quality & amp; Value Of Care For Patients
Debra Patt MD @dapattmd Of US Oncology Research Discusses Delivering Innovated Care In The Clinic: Innovations Made In The Clinic Have Been Transformative In Terms Of Improving The Quality & Value... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2019 Category: Cancer & Oncology Source Type: podcasts

Questions About mRNA: Takes 50-60 Days From Biopsy To Treating Patient, Good Scientific Rational For Expected Synergy With A Checkpoint Inhibitor
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses Questions About mRNA: Takes 50-60 Days From Biopsy To Treating Patient, Good Scientific Rational For Expected Synergy With A C... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

How Did The Patients Do: Out Of 13 Patients Treated In The Adjuvant Setting 2 Progressed & 11 Remains Disease Free
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses How Did The Patients Do: Out Of 13 Patients Treated In The Adjuvant Setting 2 Progressed & 11 Remains Disease Free. Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Emerging Data For Personalized Vaccine Approach: Safety Profile Was Clean & No Dose Limiting Toxicities, Reached 1mg Dose, Moving Into A Phase 2 Study
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses Emerging Data For Personalized Vaccine Approach: Safety Profile Was Clean & No Dose Limiting Toxicities, Reached 1mg Dose, Mov... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and pa
Geraldine O' Sullivan Coyne, MD, discusses the Phase I Trial fo Murlentamab.Background:Membranous expression of AMHRII is found in ~70% of gynecological tumors. Murlentamab (M) binds with high a... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

(Spanish) First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin
Geraldine O' Sullivan Coyne, MD, discusses the Phase I Trial of Murlentamab.Background:Membranous expression of AMHRII is found in ~70% of gynecological tumors. Murlentamab (M) binds with high a... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

The Road To Regulatory Approval
Scott Koenig, of Macrogenics, discusses what it will take to gain regulatory approval.About MacroGenics, Inc.MacroGenics is a clinical-stage biopharmaceutical company focused on discovering an... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Achieveing a Better Outcome For Patients
Scott Koenig, of Macrogenics, discusses achieving a better outcome for patients.About MacroGenics, Inc.MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and deve... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Scott Koenig discusses the data on the Phase 3 SOPHIA study.About MacroGenics, Inc.MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative mo... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Phase 3 SOPHIA Study
Scott Koenig discusses the Phase 3 SOPHIA study.About MacroGenics, Inc.MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal ant... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Caring For Every Patient And Learning From Every Patient
Yousuf Zafar, MD, discusses the importance of patient care.Financial barriers to clinical trial enrollment are an area of active investigation. Financial toxicity as a concept describes how high c... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

The Quality and Completeness of Data
Yousuf Zafar, MD, discusses the importance of questioning the qaulity and completenesss of Data.Financial barriers to clinical trial enrollment are an area of active investigation. Financial toxicit... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Financial Toxicity and Equitable Access to Clinical Trials
Yousuf Zafar, MD, discuses the role of Real World Evidence in cancer care.Financial barriers to clinical trial enrollment are an area of active investigation. Financial toxicity as a concept descr... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Dr. Mehool Patel dicusses how artificial intelligence makes an impact on decisions for both clinicians and patients alike.Background:Next generation sequencing (NGS) in hematological tumors is i... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

The Importance of Minimal Residual Disease Negativity
Rod Humerickhouse discusses the importance of Minimal Residual Disease Negativity.Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG treatment w... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and c
Rod Humerickhouse discusses the Phase 3 CLL14 Trial.Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG treatment with chlorambucil-obinutuzumab ... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

The Broad Implications of The SUAL Study
Dr. Cora Sternberg discusses the broader implications of the SAUL study.Background: Atezo, a monoclonal antibody targeting PD-L1, is an approved therapy for locally advanced/metastatic UC based ... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

The Broad Implications of The SAUL Study
Dr. Cora Sternberg Of Weill Cornell Medicine and NewYork-Presbyterian discusses the broader implications of the SAUL study.Background: Atezo, a monoclonal antibody targeting PD-L1, is an approved ... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.
Dr. Cora Sternberg discusses results of the SAUL study.Background: Atezo, a monoclonal antibody targeting PD-L1, is an approved therapy for locally advanced/metastatic UC based on IMvigor210 and I... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.
Dr. Sanjay Popat, Phd, with Royal Marden Hospital, comments on Abrstract Presentation: Results from a Phase II single-agent trial.Background: Lurbinectedin (L) is a novel anticancer drug that inhi... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

What Do The Results From The KEYNOTE-001 Mean For The Patient
Edward B. Garon discusses what the results of the KEYNOTE-001 mean for the patient.Background: Pembrolizumab (pembro) monotherapy has demonstrated durable antitumor activity in advanced PD-L1ex... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts